Sensyne Health (SENS)

Sector:

Health Care

Index:

FTSE AIM All-Share

47.50p
   
  • Change Today:
    -0.50p
  • 52 Week High: 187.50p
  • 52 Week Low: 39.50p
  • Currency: UK Pounds
  • Shares Issued: 128.57m
  • Volume: 13,797
  • Market Cap: £61.07m
  • RiskGrade: 446

Sensyne Health reveals Cognizant and Agorai as US partners

By Josh White

Date: Friday 15 Nov 2019

LONDON (ShareCast) - (Sharecast News) - Clinical artificial intelligence (AI) technology company Sensyne Health revealed the names of its partners for the launch and sale of its digital health software products in the United States on Friday.
The AIM-trade firm had announced signed agreements with a Fortune 200 company and a data infrastructure specialist on 7 October, but did not name them at the time.

On Friday, it confirmed that Cognizant - the American multinational corporation and provider of information technology, consulting, and business process services in healthcare - and data infrastructure specialist Agorai, as its partners.

The firm said the initial Sensyne Health digital health software products that would be exclusively sold in the US under the agreements would be 'GDm-Health', for the management of gestational diabetes; 'EDGE', for the management of COPD; and 'Support-HF', for the management of heart failure.

It said GDm-health would be launched first, with the product currently in use by 15 NHS Trusts, having helped more than 6,100 patients in the UK managing and controlling gestational diabetes, a common condition that could lead to high blood pressure, premature birth or the need for Caesarean section.

No UK patient data would be shared under the agreements, the board confirmed.

The products were originally invented and developed in the UK's NHS in collaboration with the University of Oxford, and then licensed to Sensyne Health.

It said the financial returns made by Sensyne Health under the agreements with Cognizant and Agorai would be shared with the NHS under its unique partnership model.

"Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK's NHS, is realised in the US market," said chief executive officer Lord Drayson.

"Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS."

At 1141 GMT, shares in Sensyne Health were up 2.68% at 102.68p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Sensyne Health Market Data

Currency UK Pounds
Share Price 47.50p
Change Today -0.50p
% Change -1.04 %
52 Week High 187.50p
52 Week Low 39.50p
Volume 13,797
Shares Issued 128.57m
Market Cap £61.07m
RiskGrade 446

Sensyne Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
23.07% above the market average23.07% above the market average23.07% above the market average23.07% above the market average23.07% above the market average
61.11% above the sector average61.11% above the sector average61.11% above the sector average61.11% above the sector average61.11% above the sector average
Price Trend
68.29% below the market average68.29% below the market average68.29% below the market average68.29% below the market average68.29% below the market average
65.85% below the sector average65.85% below the sector average65.85% below the sector average65.85% below the sector average65.85% below the sector average
Income Not Available
Growth
14.99% above the market average14.99% above the market average14.99% above the market average14.99% above the market average14.99% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Sensyne Health Dividends

No dividends found

Trades for 21-Feb-2020

Time Volume / Share Price
15:31 1,023 @ 47.77p
14:40 1,033 @ 47.99p
14:08 1,052 @ 47.50p
12:17 1,000 @ 47.50p
09:43 565 @ 47.00p

Sensyne Health Key Personnel

CEO Paul Drayson
CFO Lorimer Headley

Top of Page